08.29.25 -- STREAM Edition: Biotech Product Partnership with Coya Therapeutics

In this discussion, Mid Atlantic Bio Angels founder Yaniv Sneor details their considerations when deliberating whether to invest in a biotech startup. The group prioritizes understanding how each biotech plans to monetize its opportunity and achieve a successful exit within five to seven years — looking for a clear path, potential acquirers, and comparable deals — so commercial mindset is as important as scientific prowess.

If you are in the process of developing a complex or sensitive injectable drug, learn about containment solutions to mitigate your risks and help you get your drug to the patient faster.

On this episode of Better Biopharma, Interius BioTherapeutics’ Sianny Christanti and Babu Medi, Ph.D., explain how the company is re-engineering a lentiviral vector to enable INT2104, its off-the-shelf, in vivo CAR T-cell therapy. They discuss the vector's design and its manufacturability, as well as the analytical and regulatory challenges of bringing this first-in-human therapy to the clinic.

Learn about high throughput biologic automation and GMP master cell banking services as well as variable selection services that search the SQL space to find promoters.

 On this week's Business Of Biotech episode, Milan Kalawadia, CEO, North America, Dr. Reddy's Laboratories, and Arun Swaminathan, Ph.D., CEO, Coya Therapeutics discuss their unique partnership to develop COYA 302, a novel dual-mechanism immunotherapy for the treatment of ALS. 

Explore how AI is transforming visual inspection and gain a deep understanding of defect detection, real-time performance, and integration challenges.

This scalable, automated system ensures high cell viability and recovery, efficient concentration and washing, and fast processing. Experience the power of tubular bowl technology for optimal cell separation.